NCT04494373View on ClinicalTrials.gov

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

PHASE1UnknownINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
Bone Metastasis From Solid Tumors
Interventions
DRUG

HS-20090

A human IgG2 monoclonal antibody with affinity and specificity for human RANKL

DRUG

Xgeva®

A human IgG2 monoclonal antibody with affinity and specificity for human RANKL

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY

NCT04494373 - Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults | Biotech Hunter | Biotech Hunter